Tagged with Hungary

Hungary Among the efforts of Hungarian stakeholders to determine more efficient pricing and reimbursement structures, there is a common ambition to explore what is considered by many to be the next epoch of healthcare; a value-based system.   The cost of healthcare in Hungary is increasing at least twice as fast…

Hungary In 2016, Hungary transitioned from a second-tier member to a full member of the EU. As Judit Bidló, deputy director general of pricing and reimbursement for Hungary’s National Institute of Health Insurance Fund Management (NEAK), explains, this has already had a significant impact on patient access to innovative new products.…

Hungary Tamás Demeter, Country Manager for AOP Orphan shares his insights on the footprint of the company in Hungary, the areas of therapeutic need that AOP caters to, the performance of 2019 and its key achievements, the ecosystem of rare diseases in Hungary, and patient awareness while highlighting the role of…

Hungary Katinka Zinnemers, managing director of Abacus Medicine, highlights the company’s mission to increase access to medicines for all patients and its commitment to building trust with authorities as it enters into the arena of parallel imports.     As a parallel trade company, we must be compliant in the same manner…

Hungary Csaba Kis, CEO of Qualiskills, shares his insights on the packaging capabilities of the company, its sustainable competitive advantage, the impact of the European serialization guidelines, and the company’s strategic objectives for the future.   With the Falsified Medicines Directive of February 9, almost all drugs within the EU had…

Hungary MD Pál Szamosújvari, Judit Jávor, Pál Szamosújvari Jr—Founder, R&D Director, and Director of Pharma Patent respectively—share their insights on the activities of the company, the importance of R&D, the challenges of smaller companies, its marketing strategy of its niche products, and its internationalization strategy.   Can you introduce yourself and…

Hungary Csilla Léka, general manager of Global Clinical Trials in Hungary shares her insights on the portfolio of the company, the most prevalent therapeutic areas, the developments in clinical trials over the last decade, and her outlook on the future of the company.   In comparison with Western European countries, Hungary…

Hungary Calin Galaseanu, recently appointed general manager of Novo Nordisk Hungary, elaborates on the country’s strong treatment paradigm for diabetes. He goes on to highlight Hungary’s key positioning as a strategic affiliate for Novo Nordisk in the areas of market access success and clinical trial capabilities.     Hungary is actually…

Hungary László Dene, managing director of Bellis, gives his insights on the trends affecting the wholesale supply chain and product delivery in Hungary, the strategic positioning of the company as the subsidiary of Hungaropharma – the country’s largest wholesaler – specialized in OTC healthcare products and the importance of their newly…

Hungary Gergely Jánoki CEO of Medi-Radiopharma shares his insights on the activities of the company, the trends in the radiopharmaceutical industry while highlighting regulatory trends, the importance of quality, the driving factors behind the company’s success and his long-term vision of for the company.   We grew more than 60 percent…

Hungary Dr Antal Feller, CEO of Hungaropharma, gives his insights on the pharma trends affecting the wholesale supply chain and product delivery in Hungary, the strategic positioning of the company, on the importance of their newly opened logistics centre in Budapest, the regulatory hurdle of the serialization guideline, while sharing his…

Hungary Francesco Banchi, general manager of Boehringer Ingelheim Hungary, elaborates on the successful development of the affiliate in recent years, making progress in new product reimbursement. As an experienced leader in sales and marketing, Banchi offers his insights into the challenging market access landscape of Hungary and his strategies in cooperating…